A CD4<sup>+</sup> T cell population expanded in lupus blood provides B cell help through interleukin-10 and succinate.

Caielli, Simone; Veiga, Diogo Troggian; Balasubramanian, Preetha; Athale, Shruti; Domic, Bojana; Murat, Elise; Banchereau, Romain; Xu, Zhaohui et al. · Nat Med · 2019

basic_science · Level V

Where this comes from

Abstract

Understanding the mechanisms underlying autoantibody development will accelerate therapeutic target identification in autoimmune diseases such as systemic lupus erythematosus (SLE)<sup>1</sup>. Follicular helper T cells (T<sub>FH</sub> cells) have long been implicated in SLE pathogenesis. Yet a fraction of autoantibodies in individuals with SLE are unmutated, supporting that autoreactive B cells also differentiate outside germinal centers<sup>2</sup>. Here, we describe a CXCR5<sup>-</sup>CXCR3<sup>+</sup> programmed death 1 (PD1)<sup>hi</sup>CD4<sup>+</sup> helper T cell population distinct from T<sub>FH</sub> cells and expanded in both SLE blood and the tubulointerstitial areas of individuals with proliferative lupus nephritis. These cells produce interleukin-10 (IL-10) and accumulate mitochondrial reactive oxygen species as the result of reverse electron transport fueled by succinate. Furthermore, they provide B cell help, independently of IL-21, through IL-10 and succinate. Similar cells are generated in vitro upon priming naive CD4<sup>+</sup> T cells with plasmacytoid dendritic cells activated with oxidized mitochondrial DNA, a distinct class of interferogenic toll-like receptor 9 ligand<sup>3</sup>. Targeting this pathway might blunt the initiation and/or perpetuation of extrafollicular humoral responses in SLE.

Medical subject headings